Zobrazeno 1 - 10
of 465
pro vyhledávání: '"S. Vaultier"'
Publikováno v:
Citováno v: Kuchař, Karel: Mapová sbírka B.P. Molla, s. 247
Citováno v: BNF
Citováno v: BNF
Autor:
Nieto, Susana1 (AUTHOR) inmaculada.lozanol@um.es, Lozano, Inmaculada1 (AUTHOR), Ruiz, Francisco J.1 (AUTHOR), Costa, Jose F.1 (AUTHOR), Villa, Rocio1 (AUTHOR), Lozano, Pedro1 (AUTHOR) susanani@um.es
Publikováno v:
Molecules. Nov2024, Vol. 29 Issue 21, p5057. 19p.
Autor:
M. O. Beyne-rauzy, D. Vassilieff, Lionel Adès, Stéphane Cheze, Pierre Fenaux, Sophie Park, L. Voillat, Jean-François Bernard, F. Hamza, M.C. Quarre, Claude Gardin, Lionel Mannone, S. Vaultier, Laurence Legros, P. Agape, Francois Dreyfus, Stéphane Giraudier
Publikováno v:
British Journal of Haematology. 133:513-519
An open-label, phase II non-randomised trial was conducted with darbepoetin (DAR), an erythropoiesis-stimulating factor with prolonged half-life, at a weekly dose of 300 mug subcutaneously in 62 anaemic patients with myelodysplastic syndrome (MDS) wi
Autor:
Han, Shaoxuan1,2 (AUTHOR) 20213007002@hainanu.edu.cn, Lin, Yanhui3 (AUTHOR) lyh_1012@163.com, Meng, Yayi1 (AUTHOR) 21220951310162@hainanu.edu.cn, Si, Chengcheng1,2 (AUTHOR) ccsi@hainanu.edu.cn
Publikováno v:
International Journal of Molecular Sciences. Aug2024, Vol. 25 Issue 15, p8236. 19p.
Autor:
P. Marchand G. Fouillet Y. Berthier J. Douki F. Hassine F. Gmouh S. Vaultier M., Dubois, DUBOIS, Philippe, Marchand, Gilles, Fouillet, Yves, Berthier, Jean, Douki, Thierry, Hassine, Fatima, Gmouh, Saïd, Vaultier, Michel
Publikováno v:
Analytical Chemistry
Analytical Chemistry, American Chemical Society, 2006, 78 (14), pp.4909-17. ⟨10.1021/ac060481q⟩
Analytical Chemistry, 2006, 78 (14), pp.4909-17. ⟨10.1021/ac060481q⟩
Analytical Chemistry, American Chemical Society, 2006, 78 (14), pp.4909-17. ⟨10.1021/ac060481q⟩
Analytical Chemistry, 2006, 78 (14), pp.4909-17. ⟨10.1021/ac060481q⟩
A powerful approach combining a droplet-based, open digital microfluidic lab-on-a-chip using task-specific ionic liquids as soluble supports to perform solution-phase synthesis is reported as a new tool for chemical applications. The negligible volat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2386c4a9b62608631fbf197c1eeda95f
https://hal.archives-ouvertes.fr/hal-00097914
https://hal.archives-ouvertes.fr/hal-00097914
Autor:
Boccia, Ralph1 (AUTHOR), Xiao, Hong2 (AUTHOR) tohongxiao@gmail.com, von Wilamowitz-Moellendorff, Caroline3 (AUTHOR) caroline.vonwilamowitz@evidera.com, Raorane, Renuka3 (AUTHOR) renuka.raorane@evidera.com, Deshpande, Sohan3 (AUTHOR), Klijn, Sven L.2 (AUTHOR), Yucel, Aylin2 (AUTHOR) aylin.yucel@bms.com
Publikováno v:
Journal of Clinical Medicine. May2024, Vol. 13 Issue 9, p2702. 24p.
Autor:
Yang, Xiaoqin1 (AUTHOR) cuixiyan@jlau.edu.cn, Cui, Xiyan1 (AUTHOR), Chang, Jiageng1 (AUTHOR), Wang, Jianan1 (AUTHOR), Wang, Yujue1 (AUTHOR), Liu, Haoye1 (AUTHOR), Wang, Yan1 (AUTHOR), Chen, Yanbo1 (AUTHOR), Yang, Yuhan1 (AUTHOR), Yao, Dan1 (AUTHOR), Sun, Fengjie2 (AUTHOR) fsun@ggc.edu, Zhou, Ying1 (AUTHOR) fsun@ggc.edu
Publikováno v:
Agronomy. Apr2024, Vol. 14 Issue 4, p843. 18p.
Autor:
Agnès Guerci, M.P. Chaury, E. Berger, Stéphane Courby, I. Coulibaly, Aude Charbonnier, Aspasia Stamatoullas, Pierre Fenaux, Shanti Natarajan, Francois Dreyfus, Stéphane Cheze, Gabriel Etienne, A. Lescoute, Norbert Vey, S. Vaultier, Laurence Legros, Christophe Ravoet
Publikováno v:
Blood. 110:1453-1453
Background: We (Blood.2006;107:1156) and others showed that marrow cells from high-risk MDS patients exhibit constitutive NF-kB activation. Bortezomib (BOR) is a specific inhibitor of NF-kB with limited efficacy when used alone in AML but which is po
Autor:
Caroline Elie, Francois Dreyfus, Achille Aouba, Pierre Fenaux, Agnès Guerci, Frédéric Bauduer, Martine Gardembas, Jerome Tamburini, D. Vassilief, Christian Berthou, Didier Bouscary, M.C. Quarre, S. Vaultier, Laurence Legros, Aspasia Stamatoullas, Laurence Sanhes, Jean-Jacques Sotto, Odile Beyne-Rauzy
Publikováno v:
Blood. 108:2673-2673
Background: Thal has shown some efficacy in low risk MDS, but with dose-limiting toxicity requiring discontinuation in > 50% pts (Bouscary D, BJH, 2005, 131, 609 and other groups). Thus we assessed Thal at lower dose in such MDS. Methods: From Jan 20
Autor:
Stéphane Cheze, Aspasia Stamatoullas, Francois Dreyfus, Norbert Vey, Pierre Fenaux, A. Kolb, S. Vaultier, Laurence Legros, Martine Gardembas, Borhane Slama, Ghandi Damaj, Frédéric Bauduer, Hesham Mohamed, E. Berger, M.C. Chaury, F. Hamza, Richard Delarue, D. Vassilief, Xavier Thomas, Odile Beyne-Rauzy, Lionel Adès, Agnès Guerci
Publikováno v:
Publons
Recombinant EPO, when used alone at 60 000 UI/ w, improves anemia in 25 to 30 % of low risk MDS, mainly when serum EPO level is low, and is ineffective on other cytopenias. A previous study (Blood2002,99:1578) suggested that the addition of ATRA to E